Evidence map›Paper›PMID 24696612›Full record

ArticleWorld journal of gastroenterology2014

Myofibroblastic cell activation and neovascularization predict native liver survival and development of esophageal varices in biliary atresia.

Janne S Suominen, Hanna Lampela, Päivi Heikkilä, Jouko Lohi, Hannu Jalanko, Mikko P Pakarinen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Janne S SuominenJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Hanna LampelaJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Päivi HeikkiläJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Jouko LohiJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Hannu JalankoJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Mikko P PakarinenJanne S Suominen, Hanna Lampela, Mikko P Pakarinen, Department of Pediatric Surgery, Pediatric Liver and Gut Research Group, Children's Hospital, University of Helsinki, 00290 Helsinki, Finland.
Helsinki Children's Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo study the relation between collagen 1, α-smooth muscle actin (α-SMA) and CD34 expression and the most essential portoenterostomy (PE) outcomes.

methodsLiver specimens were obtained at PE from 33 biliary atresia (BA) patients for immunohistochemical analysis of collagen 1, α-SMA and CD34. Liver biopsies from 35 organ donors were used as controls. Expression patterns were related to clinical data including age at PE, serum total and conjugated bilirubin concentration at the time of PE and during follow-up, incidence of esophageal varices in follow-up upper gastrointestinal endoscopies, and native liver survival as well as to detailed histopathological findings.

resultsCollagen 1 (16.4% vs 4.5%, P < 0.0001), α-SMA (17.9% vs 4.6%, P < 0.0001) and CD34 (4.9% vs 3.8%, P = 0.017) were markedly overexpressed in BA patients compared with controls. Patients who underwent liver transplantation by age of two years had significantly higher expression of collagen 1 (18.6% vs 13.7%, P = 0.024), α-SMA (20.4% vs 15.4%, P = 0.009) and CD34 (5.9% vs 4.0%, P = 0.029) at PE compared with native liver survivors. CD34-positive microvessels were identified in the centrizonal region close to central vein in every BA patient. In majority of BA cases (56%) neovascularization was frequent as CD34-positive microvessels were observed in over half of the hepatic lobules. In controls, the CD34-positive microvessels were rare as they were completely absent in 40 % and were found in less than 5 % of the hepatic lobules in the rest. The difference between BA patients and controls was significant (P < 0.0001). Patients who developed esophageal varices by two years had significantly higher expression of CD34 at PE compared with patients without varices (5.6% vs 4.0%, P = 0.019). Expression of α-SMA (r = 0.758, P < 0.0001) and collagen 1 (r = 0.474, P = 0.016), and the amount of CD34-positive microvessels (r = 0.356, P = 0.047) were related to patient age at PE.

conclusionHepatic myofibroblastic cell activation, fibrogenesis and neovascularization are enhanced in BA, progress with increasing PE age and relate to native liver survival and development of esophageal varices.

Indexed as

ActinsAntigens, CD34Biliary AtresiaBilirubinBiopsyCollagen Type IEsophageal and Gastric VaricesHumansImmunohistochemistryInfantInfant, NewbornJaundiceLiverMicrocirculationMuscle, SmoothMyofibroblastsActinsAntigens, CD34BilirubinCollagen Type IBiliary atresiaCD34Collagen 1Liver fibrosisNeovascularizationα-smooth muscle actin

Identifiers

PMID24696612
PMCPMC3964401
OpenAlexW1976951365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.